Arthritis - US - April 2009

Table of Contents

• Scope and Themes
• What you need to know
• Definition
• Data sources
• Consumer survey data
• Abbreviations and terms
• Abbreviations
• Terms
• Executive Summary
• Sufferers' trust in pharmacists, openness to fitness and alternative remedies spell opportunity for arthritis industry
• Marketing in the pharmacy aisle
• Arthritis fitness
• Sufferers have alternatives
• Market driven by aging population, obesity epidemic, lack of health insurance
• Half of over-65s have arthritis
• Overweight and obese at higher risk
• Lack of health insurance can impede prevention, worsen symptoms
• Brand qualities
• Biologics battle it out
• Rubs, creams, wraps, and patches vie for patient attention
• OTC remedies that emphasize arthritis will likely attract more sufferers
• Innovations: Creams, functional beverages, potential drugs
• Creams: from balms to wraps, from patches to massage oils
• Functional beverages pinpoint arthritis
• The pharmaceutical pipeline
• Advertising and promotion
• DTC spending down
• Cross-promotion vs. single-purpose ads
• TV ads typically employ "pharmamercial" theme
• The arthritis consumer
• Arthritis sufferers
• Treatment, prevention, and sources
• Attitudes and motivations
• Race and Hispanic origin
• Market Drivers
• An aging population means higher arthritis incidence
• Juvenile arthritis incidence may increase with growing child population
  • Figure 4: Population, by age, 2003-13
• Obesity is a leading contributor to OA
• High incidence of childhood obesity could lead to more adult OA cases
  • Figure 5: Prevalence of overweight and obesity among Americans, by gender and age, 1988-94 and 1999-2002
• Health insurance crisis impacts arthritis sufferers
  • Figure 6: Number of uninsured, 2001-07
• Organizations can help defray medical costs to eligible patients
• Brand Qualities
• Battle of the biologics
• The rub on rubs
• OTC remedies' contrasting arthritis approaches
• Innovation and Innovators
• Creams resonate with patients
• Functional beverages, easy-to-open lids
• Future pharmaceuticals?
• Pegloticase
• Tocilizumab
• Ustekinumab
• Oral small-molecule drugs
• Natural Product Data
• A look at glucosamine and chondroitin supplements
• Recent studies show mixed results
• Natural channel sales flat
  • Figure 7: Natural product supermarket retail sales of glucosamine, glucosamine formulas and chondroitin, at current prices, 2006-08
  • Figure 8: Natural product supermarket retail sales of glucosamine, glucosamine formulas and chondroitin, at inflation-adjusted prices, 2006-08
• Implications
• Advertising and Promotion
• Overview
• Pharmaceutical adspend down again in 2008
  • Figure 9: Pharmaceutical DTC advertisement spending, 2003-08
• Pharmaceutical cross-promotion
• Web advertising
• Enbrel
• Orencia
• Celebrex
• Aleve
• TV ads
• Humira
  • Figure 10: Abbott Labs/Humira television ad, 2008
• Orencia
  • Figure 11: Bristol-Myers Squibb/Orencia television ad, 2009
• Castiva
  • Figure 12: Humco Holding Group, Inc./Castiva television ad, 2008
• Celebrex
  • Figure 13: Pfizer/Celebrex television ad, 2009
• Enbrel
  • Figure 14: Wyeth (Pfizer)-Amgen/Enbrel television ad, 2008
• RAinsider
  • Figure 15: Wyeth (Pfizer)-Amgen/RAinsider television ad, 2008
• Arthritis Sufferers
• Key points
• Arthritis sufferers
  • Figure 16: Incidence of arthritis and other arthritic ailments, by gender and age, February 2009
  • Figure 17: Incidence of osteoarthritis and rheumatoid arthritis, by gender and age, July 2007-September 2008
• Location of suffering
  • Figure 18: Location of arthritis and other arthritic ailments, by gender and age, February 2009
• Symptom severity
  • Figure 19: Severity of osteoarthritis, rheumatoid arthritis, or any arthritis, by gender and age, July 2007-September 2008
• Current Treatment Approaches
• Key points
• OTC remedies top treatment methods, alternative options close behind
• Less commonly used methods offer possibilities for treatment development
  • Figure 20: Current treatment methods for arthritis, by gender and age, February 2009
  • Figure 21: Current treatment methods for arthritis, by HH income, February 2009
• Medications
• Key points
• OTC vs. Rx
  • Figure 22: Use of Rx and OTC medications for osteoarthritis, rheumatoid arthritis, or any arthritis, by gender and age, July 2007-September 2008
  • Figure 23: Use of Rx and OTC medications for osteoarthritis, rheumatoid arthritis, or any arthritis, by HH income, July 2007-September 2008
• Use of headache/pain relievers, wraps/liquids/rubs
  • Figure 24: Use of headache/pain relievers for arthritis or rheumatism, by gender and age, July 2007-September 2008
  • Figure 25: Use of headache/pain relievers for arthritis or rheumatism, by HH income, July 2007-September 2008
  • Figure 26: Use of pain relieving rubs/liquids/wraps for arthritic pain, by gender and age, July 2007-September 2008
  • Figure 27: Use of pain relieving rubs/liquids for arthritic pain, by HH income, July 2007-September 2008
• Preferential Treatment and Prevention Methods
• Key points
• Treatment method interest
  • Figure 28: Somewhat/very interested in potential methods for treating arthritis, by gender, February 2009
• Preferred prevention methods
  • Figure 29: Steps taken to prevent/delay arthritis, February 2009
• Where to Turn for Arthritis Information
• Key points
• Preferred professional sources for arthritis information
  • Figure 30: Preferred professional sources for arthritis information, by gender and age, February 2009
• Other people and media as information sources
  • Figure 31: Sources for healthcare information, by type of arthritis, July 2007-September 2008
  • Figure 32: Preferred alternate sources for arthritis information, by gender and age, February 2009
• Affluence impacts health source reliance
  • Figure 33: Select sources for arthritis information, by HH income, February 2009
• Consulting health professionals
  • Figure 34: Types of healthcare professionals consulted in the last 12 months, by type of arthritis, July 2007-September 2008
• Attitudes and Motivations
• Key points
• Attitudes towards arthritis
  • Figure 35: Attitudes towards arthritis, by gender and age, February 2009
• Activity limitations
  • Figure 36: Activities limited by arthritis, by gender and age, February 2009
• Race and Hispanic Origin
• Key points
• Arthritis sufferers
  • Figure 37: Incidence of arthritis and other arthritic ailments, by race/Hispanic origin, February 2009
• Location of suffering
  • Figure 38: Location of arthritis and other arthritic ailments, by race/Hispanic origin, February 2009
• Symptom severity
  • Figure 39: Severity of osteoarthritis, rheumatoid arthritis, or any arthritis, by race/Hispanic origin, July 2007-September 2008
• Alternative methods key in treatment
  • Figure 40: Current treatment methods for arthritis, by race/Hispanic origin, February 2009
  • Figure 41: Use of Rx and OTC medications for osteoarthritis, rheumatoid arthritis, or any arthritis, by race/Hispanic origin, July 2007-September 2008
• Preferred sources for arthritis information
  • Figure 42: Types of healthcare professionals consulted in the last 12 months, by race/Hispanic origin, July 2007-September 2008
• Appendix: Other Useful Consumer Tables
• Preferred sources for arthritis information
  • Figure 57: Preferred sources for arthritis information, by HH income, February 2009
• Attitudes and motivations
  • Figure 58: Attitudes towards arthritis, by HH income, February 2009
  • Figure 59: Activities limited by arthritis, by HH income, February 2009
• Incidence and treatment
  • Figure 60: Incidence of osteoarthritis and rheumatoid arthritis, by race/Hispanic origin, July 2007-September 2008
  • Figure 61: Use of headache/pain relievers for arthritis or rheumatism, by race/Hispanic origin, July 2007-September 2008
  • Figure 62: Use of pain relieving rubs/liquids/wraps, and use for arthritis, by race/Hispanic origin, July 2007-September 2008
• Appendix: Trade Associations